Sun’s chief Dilip Shanghvi talks about partnering intent for the firm’s GLP-1 candidate, which he hopes can complete studies in an accelerated timeframe, while legal action in the US has a cast a shadow on launch timelines of the Indian drug maker's alopecia areata treatment.

McKinsey & Company’s senior partner and lead, life sciences practice (Asia), talks to Scrip about innovation niches that could interest Indian firms including the ADC space, using AI to increase confidence in research activities and how India could leverage big pharma’s expanding global capability centres (GCCs) to shape the wider R&D ecosystem.

Sun’s CEO (North America) Abhay Gandhi tells Scrip how not many gave the firm a chance in the US with Ilumya, now with global sales of over half a billion dollars, and outlines prospects of deuruxolitinib for alopecia areata. India’s top-ranked drug maker also has an eye on China R&D assets.

The UK biotech unveils Phase II data showing an ability to reduce severity of mild-to-moderate AA, with full hair restoration in some patients. If approved, STS-01 will compete with Olumiant and Litfulo.